Covid-19 roundup: Squab­bles with gov­ern­ment de­lay Mod­er­na’s PhI­II — re­ports; No­vavax se­cures largest Warp Speed deal yet: $1.6B

A much-an­tic­i­pat­ed Phase III tri­al for Mod­er­na’s Covid-19 vac­cine is be­ing held up as the com­pa­ny de­layed sub­mit­ting tri­al pro­to­cols and sparred with gov­ern­ment sci­en­tists on how to run the study and even what the bench­mark for suc­cess should be, Reuters re­port­ed.

Mod­er­na, the first US com­pa­ny to put their vac­cine in­to hu­man test­ing, was sup­posed to en­ter a 30,000-per­son study this month in part­ner­ship with the NIH to de­ter­mine whether it can pre­vent in­fec­tion. STAT re­port­ed last week that the tri­al was fac­ing de­lays over the pro­to­col, but that a Ju­ly start was still pos­si­ble. Nei­ther the NIH nor Mod­er­na ever dis­closed a spe­cif­ic date the tri­al should start, but Reuters re­port­ed that the agency had hoped to be­gin on Ju­ly 10.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA